Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Eplerenone 50mg Clear all
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

NCT01807221
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo, Inspra (eplerenone)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 10, 2026, 3:37 PM EDT
Recruiting Phase 4 Interventional

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

NCT05030545
View directory record Official record
Conditions
Primary Aldosteronism, Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 10, 2026, 3:37 PM EDT
Terminated Phase 4 Interventional Results available

The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease

NCT01971593
View directory record Official record
Conditions
Tetralogy of Fallot, Transposition of the Great Vessels With an Arterial Switch, Single Ventricle With a Fontan Palliation
Interventions
Eplerenone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Sep 10, 2026, 3:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

NCT02525796
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
eplerenone, amiloride, Placebo, Cinacalcet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 10, 2026, 3:37 PM EDT
Completed Phase 4 Interventional Results available

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

NCT02034435
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Low Salt diet plus Placebo tablet, Low Sodium diet plus Salt tablet, Epleronone, Amlodipine
Other · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 10, 2026, 3:37 PM EDT
Completed Not applicable Interventional Results available

Eplerenone in HIV Associated Abdominal Fat Accumulation

NCT01405456
View directory record Official record
Conditions
HIV
Interventions
Eplerenone and lifestyle, placebo and lifestyle
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 10, 2026, 3:37 PM EDT
Completed Not applicable Interventional Results available

Eplerenone for the Treatment of Central Serous Chorioretinopathy

NCT01990677
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
25mg Eplerenone, Placebo
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Cherry Hill, New Jersey • Marlton, New Jersey • Mays Landing, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 10, 2026, 3:37 PM EDT
Withdrawn Phase 4 Interventional

Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)

NCT04746495
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, Eplerenone 50mg
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 10, 2026, 3:37 PM EDT
Completed Not applicable Interventional Results available

Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)

NCT02740179
View directory record Official record
Conditions
HIV
Interventions
Eplerenone, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 10, 2026, 3:37 PM EDT
Terminated Phase 2 Interventional

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

NCT01373086
View directory record Official record
Conditions
Hypertension
Interventions
LFF269, Eplerenone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
11
States / cities
Anaheim, California • Fort Myers, Florida • Miramar, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 10, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Eplerenone for Central Serous Chorioretinopathy

NCT01822561
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
Eplerenone 50mg
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 10, 2026, 3:37 PM EDT
Terminated Phase 4 Interventional

Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure

NCT00293150
View directory record Official record
Conditions
Diastolic Heart Failure
Interventions
Eplerenone
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 10, 2026, 3:37 PM EDT
Completed Phase 3 Interventional Results available

Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

NCT02354352
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Eplerenone, Spironolactone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
7 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 10, 2026, 3:37 PM EDT
Completed Phase 4 Interventional Results available

Diurnal Variation of Plasminogen Activator Inhibitor-1

NCT00515021
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Eplerenone (Morning), Eplerenone (Night-time)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 10, 2026, 3:37 PM EDT
Terminated Not applicable Interventional

A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives

NCT00825188
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
eplerenone, amlodipine, eplerenone, amlodipine
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
21 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Sep 10, 2026, 3:37 PM EDT